Global (North America, Europe and Asia-Pacific, South America, Middle East and Africa) Drugs for Vulvovaginal Candidiasis Market 2018 Forecast to 2023
Published On: March 2018
 
Report ID:206181
 
Category: Healthcare
 
Pages: 101




The cell wall of Candida is a complex glycoprotein that depends on the biosynthesis of ergosterol. Azole compounds, found in antimycotic drugs, are believed to block ergosterol production, allowing topical antimycotics to achieve cure rates in excess of 80%. The only oral azole agent approved for this indication by the US Food and Drug Administration (FDA) is fluconazole, which also achieves a high cure rate. Therapeutic concentrations are found in vaginal secretions for at least 72 hours after the ingestion of a single 150-mg tablet.
Scope of the Report:
This report focuses on the Drugs for Vulvovaginal Candidiasis in Global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
Bayer
Perrigo
J & J
Pfizer
Bristol-Myers Squibb
Effik
Teva
Sanofi
Cisen Pharmaceutical
Kingyork Group
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Miconazole
Clotrimazole
Fluconazole
Econazole
Other
Market Segment by Applications, can be divided into
Hospital & Clinic
Pharmacy
There are 15 Chapters to deeply display the global Drugs for Vulvovaginal Candidiasis market.
Chapter 1, to describe Drugs for Vulvovaginal Candidiasis Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Drugs for Vulvovaginal Candidiasis, with sales, revenue, and price of Drugs for Vulvovaginal Candidiasis, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Drugs for Vulvovaginal Candidiasis, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Drugs for Vulvovaginal Candidiasis market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Drugs for Vulvovaginal Candidiasis sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
Table of Contents
1 Market Overview
1.1 Drugs for Vulvovaginal Candidiasis Introduction
1.2 Market Analysis by Type
1.2.1 Miconazole
1.2.2 Clotrimazole
1.2.3 Fluconazole
1.2.4 Econazole
1.2.5 Other
1.3 Market Analysis by Applications
1.3.1 Hospital & Clinic
1.3.2 Pharmacy
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2013-2023)
1.4.1.2 Canada Market States and Outlook (2013-2023)
1.4.1.3 Mexico Market States and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2013-2023)
1.4.2.2 France Market States and Outlook (2013-2023)
1.4.2.3 UK Market States and Outlook (2013-2023)
1.4.2.4 Russia Market States and Outlook (2013-2023)
1.4.2.5 Italy Market States and Outlook (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2013-2023)
1.4.3.2 Japan Market States and Outlook (2013-2023)
1.4.3.3 Korea Market States and Outlook (2013-2023)
1.4.3.4 India Market States and Outlook (2013-2023)
1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2013-2023)
1.4.4.2 Egypt Market States and Outlook (2013-2023)
1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
1.4.4.4 South Africa Market States and Outlook (2013-2023)
1.4.4.5 Nigeria Market States and Outlook (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Bayer
2.1.1 Business Overview
2.1.2 Drugs for Vulvovaginal Candidiasis Type and Applications
2.1.2.1 Type 1
2.1.2.2 Type 2
2.1.3 Bayer Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 Perrigo
2.2.1 Business Overview
2.2.2 Drugs for Vulvovaginal Candidiasis Type and Applications
2.2.2.1 Type 1
2.2.2.2 Type 2
2.2.3 Perrigo Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 J & J
2.3.1 Business Overview
2.3.2 Drugs for Vulvovaginal Candidiasis Type and Applications
2.3.2.1 Type 1
2.3.2.2 Type 2
2.3.3 J & J Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4 Pfizer
2.4.1 Business Overview
2.4.2 Drugs for Vulvovaginal Candidiasis Type and Applications
2.4.2.1 Type 1
2.4.2.2 Type 2
2.4.3 Pfizer Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5 Bristol-Myers Squibb
2.5.1 Business Overview
2.5.2 Drugs for Vulvovaginal Candidiasis Type and Applications
2.5.2.1 Type 1
2.5.2.2 Type 2
2.5.3 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6 Effik
2.6.1 Business Overview
2.6.2 Drugs for Vulvovaginal Candidiasis Type and Applications
2.6.2.1 Type 1
2.6.2.2 Type 2
2.6.3 Effik Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.7 Teva
2.7.1 Business Overview
2.7.2 Drugs for Vulvovaginal Candidiasis Type and Applications
2.7.2.1 Type 1
2.7.2.2 Type 2
2.7.3 Teva Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.8 Sanofi
2.8.1 Business Overview
2.8.2 Drugs for Vulvovaginal Candidiasis Type and Applications
2.8.2.1 Type 1
2.8.2.2 Type 2
2.8.3 Sanofi Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.9 Cisen Pharmaceutical
2.9.1 Business Overview
2.9.2 Drugs for Vulvovaginal Candidiasis Type and Applications
2.9.2.1 Type 1
2.9.2.2 Type 2
2.9.3 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.10 Kingyork Group
2.10.1 Business Overview
2.10.2 Drugs for Vulvovaginal Candidiasis Type and Applications
2.10.2.1 Type 1
2.10.2.2 Type 2
2.10.3 Kingyork Group Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
3 Global Drugs for Vulvovaginal Candidiasis Market Competition, by Manufacturer
3.1 Global Drugs for Vulvovaginal Candidiasis Sales and Market Share by Manufacturer (2016-2017)
3.2 Global Drugs for Vulvovaginal Candidiasis Revenue and Market Share by Manufacturer (2016-2017)
3.3 Global Drugs for Vulvovaginal Candidiasis Price by Manufacturer (2016-2017)
3.4 Market Concentration Rate
3.4.1 Top 3 Drugs for Vulvovaginal Candidiasis Manufacturer Market Share in 2017
3.4.2 Top 5 Drugs for Vulvovaginal Candidiasis Manufacturer Market Share in 2017
3.5 Market Competition Trend
4 Global Drugs for Vulvovaginal Candidiasis Market Analysis by Regions
4.1 Global Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Regions
4.1.1 Global Drugs for Vulvovaginal Candidiasis Sales by Regions (2013-2018)
4.1.2 Global Drugs for Vulvovaginal Candidiasis Revenue by Regions (2013-2018)
4.2 North America Drugs for Vulvovaginal Candidiasis Sales, Revenue and Growth Rate (2013-2018)
4.3 Europe Drugs for Vulvovaginal Candidiasis Sales, Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales, Revenue and Growth Rate (2013-2018)
4.5 South America Drugs for Vulvovaginal Candidiasis Sales, Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales, Revenue and Growth Rate (2013-2018)
5 North America Drugs for Vulvovaginal Candidiasis by Countries, Type, Application and Manufacturers
5.1 North America Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Countries
5.1.1 North America Drugs for Vulvovaginal Candidiasis Sales by Countries (2013-2018)
5.1.2 North America Drugs for Vulvovaginal Candidiasis Revenue by Countries (2013-2018)
5.1.3 United States Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
5.1.4 Canada Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
5.1.5 Mexico Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
5.2 North America Drugs for Vulvovaginal Candidiasis Sales and Revenue (Value) by Manufacturers (2016-2017)
5.2.1 North America Drugs for Vulvovaginal Candidiasis Sales by Manufacturers (2016-2017)
5.2.2 North America Drugs for Vulvovaginal Candidiasis Revenue by Manufacturers (2016-2017)
5.3 North America Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Type (2013-2018)
5.3.1 North America Drugs for Vulvovaginal Candidiasis Sales and Sales Share by Type (2013-2018)
5.3.2 North America Drugs for Vulvovaginal Candidiasis Revenue and Revenue Share by Type (2013-2018)
5.4 North America Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Application (2013-2018)
5.4.1 North America Drugs for Vulvovaginal Candidiasis Sales and Sales Share by Application (2013-2018)
5.4.2 North America Drugs for Vulvovaginal Candidiasis Revenue and Revenue Share by Application (2013-2018)
6 Europe Drugs for Vulvovaginal Candidiasis by Countries, Type, Application and Manufacturers
6.1 Europe Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Countries
6.1.1 Europe Drugs for Vulvovaginal Candidiasis Sales by Countries (2013-2018)
6.1.2 Europe Drugs for Vulvovaginal Candidiasis Revenue by Countries (2013-2018)
6.1.3 Germany Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
6.1.4 UK Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
6.1.5 France Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
6.1.6 Russia Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
6.1.7 Italy Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
6.2 Europe Drugs for Vulvovaginal Candidiasis Sales and Revenue (Value) by Manufacturers (2016-2017)
6.2.1 Europe Drugs for Vulvovaginal Candidiasis Sales by Manufacturers (2016-2017)
6.2.2 Europe Drugs for Vulvovaginal Candidiasis Revenue by Manufacturers (2016-2017)
6.3 Europe Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Type (2013-2018)
6.3.1 Europe Drugs for Vulvovaginal Candidiasis Sales and Sales Share by Type (2013-2018)
6.3.2 Europe Drugs for Vulvovaginal Candidiasis Revenue and Revenue Share by Type (2013-2018)
6.4 Europe Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Application (2013-2018)
6.4.1 Europe Drugs for Vulvovaginal Candidiasis Sales and Sales Share by Application (2013-2018)
6.4.2 Europe Drugs for Vulvovaginal Candidiasis Revenue and Revenue Share by Application (2013-2018)
7 Asia-Pacific Drugs for Vulvovaginal Candidiasis by Countries, Type, Application and Manufacturers
7.1 Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Countries
7.1.1 Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales by Countries (2013-2018)
7.1.2 Asia-Pacific Drugs for Vulvovaginal Candidiasis Revenue by Countries (2013-2018)
7.1.3 China Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
7.1.4 Japan Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
7.1.5 Korea Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
7.1.6 India Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
7.1.7 Southeast Asia Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
7.2 Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales and Revenue (Value) by Manufacturers (2016-2017)
7.2.1 Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales by Manufacturers (2016-2017)
7.2.2 Asia-Pacific Drugs for Vulvovaginal Candidiasis Revenue by Manufacturers (2016-2017)
7.3 Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Type (2013-2018)
7.3.1 Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales and Sales Share by Type (2013-2018)
7.3.2 Asia-Pacific Drugs for Vulvovaginal Candidiasis Revenue and Revenue Share by Type (2013-2018)
7.4 Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Application (2013-2018)
7.4.1 Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales and Sales Share by Application (2013-2018)
7.4.2 Asia-Pacific Drugs for Vulvovaginal Candidiasis Revenue and Revenue Share by Application (2013-2018)
8 South America Drugs for Vulvovaginal Candidiasis by Countries, Type, Application and Manufacturers
8.1 South America Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Countries
8.1.1 South America Drugs for Vulvovaginal Candidiasis Sales by Countries (2013-2018)
8.1.2 South America Drugs for Vulvovaginal Candidiasis Revenue by Countries (2013-2018)
8.1.3 Brazil Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
8.1.4 Argentina Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
8.1.5 Colombia Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
8.2 South America Drugs for Vulvovaginal Candidiasis Sales and Revenue (Value) by Manufacturers (2016-2017)
8.2.1 South America Drugs for Vulvovaginal Candidiasis Sales by Manufacturers (2016-2017)
8.2.2 South America Drugs for Vulvovaginal Candidiasis Revenue by Manufacturers (2016-2017)
8.3 South America Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Type (2013-2018)
8.3.1 South America Drugs for Vulvovaginal Candidiasis Sales and Sales Share by Type (2013-2018)
8.3.2 South America Drugs for Vulvovaginal Candidiasis Revenue and Revenue Share by Type (2013-2018)
8.4 South America Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Application (2013-2018)
8.4.1 South America Drugs for Vulvovaginal Candidiasis Sales and Sales Share by Application (2013-2018)
8.4.2 South America Drugs for Vulvovaginal Candidiasis Revenue and Revenue Share by Application (2013-2018)
9 Middle East and Africa Drugs for Vulvovaginal Candidiasis by Countries, Type, Application and Manufacturers
9.1 Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales by Countries (2013-2018)
9.1.2 Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue by Countries (2013-2018)
9.1.3 Saudi Arabia Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
9.1.4 UAE Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
9.1.5 Egypt Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
9.1.6 Nigeria Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
9.1.7 South Africa Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
9.2 Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales and Revenue (Value) by Manufacturers (2016-2017)
9.2.1 Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales by Manufacturers (2016-2017)
9.2.2 Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue by Manufacturers (2016-2017)
9.3 Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Type (2013-2018)
9.3.1 Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales and Sales Share by Type (2013-2018)
9.3.1 Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue and Revenue Share by Type (2013-2018)
9.4 Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Application (2013-2018)
9.4.1 Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales and Sales Share by Application (2013-2018)
9.4.2 Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue and Revenue Share by Application (2013-2018)
10 Global Drugs for Vulvovaginal Candidiasis Market Segment by Type
10.1 Global Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Type (2013-2018)
10.1.1 Global Drugs for Vulvovaginal Candidiasis Sales and Market Share by Type (2013-2018)
10.1.2 Global Drugs for Vulvovaginal Candidiasis Revenue and Market Share by Type (2013-2018)
10.2 Miconazole Sales Growth and Price
10.2.1 Global Miconazole Sales Growth (2013-2018)
10.2.2 Global Miconazole Price (2013-2018)
10.3 Clotrimazole Sales Growth and Price
10.3.1 Global Clotrimazole Sales Growth (2013-2018)
10.3.2 Global Clotrimazole Price (2013-2018)
10.4 Fluconazole Sales Growth and Price
10.4.1 Global Fluconazole Sales Growth (2013-2018)
10.4.2 Global Fluconazole Price (2013-2018)
10.5 Econazole Sales Growth and Price
10.5.1 Global Econazole Sales Growth (2013-2018)
10.5.2 Global Econazole Price (2013-2018)
10.6 Other Sales Growth and Price
10.6.1 Global Other Sales Growth (2013-2018)
10.6.2 Global Other Price (2013-2018)
11 Global Drugs for Vulvovaginal Candidiasis Market Segment by Application
11.1 Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2013-2018)
11.2 Hospital & Clinic Sales Growth (2013-2018)
11.3 Pharmacy Sales Growth (2013-2018)
12 Drugs for Vulvovaginal Candidiasis Market Forecast (2018-2023)
12.1 Global Drugs for Vulvovaginal Candidiasis Sales, Revenue and Growth Rate (2018-2023)
12.2 Drugs for Vulvovaginal Candidiasis Market Forecast by Regions (2018-2023)
12.2.1 North America Drugs for Vulvovaginal Candidiasis Market Forecast (2018-2023)
12.2.2 Europe Drugs for Vulvovaginal Candidiasis Market Forecast (2018-2023)
12.2.3 Asia-Pacific Drugs for Vulvovaginal Candidiasis Market Forecast (2018-2023)
12.2.4 South America Drugs for Vulvovaginal Candidiasis Market Forecast (2018-2023)
12.2.5 Middle East and Africa Drugs for Vulvovaginal Candidiasis Market Forecast (2018-2023)
12.3 Drugs for Vulvovaginal Candidiasis Market Forecast by Type (2018-2023)
12.3.1 Global Drugs for Vulvovaginal Candidiasis Sales Forecast by Type (2018-2023)
12.3.2 Global Drugs for Vulvovaginal Candidiasis Market Share Forecast by Type (2018-2023)
12.4 Drugs for Vulvovaginal Candidiasis Market Forecast by Application (2018-2023)
12.4.1 Global Drugs for Vulvovaginal Candidiasis Sales Forecast by Application (2018-2023)
12.4.2 Global Drugs for Vulvovaginal Candidiasis Market Share Forecast by Application (2018-2023)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
1

Please fill the form below, to recieve the report sample

Name*
Email*
Phone*
Name of the Company*
Title / Designation*
Country*
Your specific requirements*
Human Verification*

Please fill the form below for enquiry

Name*
Email*
Phone*
Name of the Company*
Title / Designation*
Country*
Your specific requirements*
Human Verification*
   Our Clients
  • \


Copyright © 2019 Fior Market Research LLP, All Rights Reserved.